Angeion: Life After St. Jude
Executive Summary
Angeion thought it was going to get to the implantable defibrillator market with St. Jude as a marketing partner. But St. Jude's acquisition of Ventritex changed all that. Now, Angeion is going it alone, with worldwide royalty-free licenses from St. Jude on a wide range of patents. But can Angeion use that base and what company officials believe is superior technology to succeed in a market increasingly dominated by giants?
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.